A research team led by Prof. Liu Chenli from the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences (CAS) and Prof. Xiao Yichuan from the Shanghai Institute of Nutrition and Health of CAS elucidated the mechanism behind bacterial cancer therapy using a genetically engineered bacterial strain. Their findings were published in Cell on March 3. Exploring the use of antitumor bacteria in cancer therapy dates back to the 1860s. Despite this long history, however, clinical application of bacterial-based cancer therapy has faced significant challenges in terms of safety and efficacy. Recent advancements in synthetic biology have enabled...